Artificial Intelligence (AI) has achieved remarkable successes in recent years. It can defeat human champions in games like Go, predict protein structures with high accuracy, and perform complex tasks ...
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...
When we use words to communicate, we not only have to choose what to say, but also what not to say, and how to say it. How we decide to frame a message can influence how people think, feel, and ...
On September 1st, the author and statistician Nate Silver wrote a post on X diagnosing a new condition: “Blueskyism,” so named for the decentralized social network that has emerged as a competitor to ...
Dashia is the consumer insights editor for CNET. She specializes in data-driven analysis and news at the intersection of tech, personal finance and consumer sentiment. Dashia investigates economic ...
A burst of experimentation followed ChatGPT's release to the public in late 2022. Now many people are integrating the newest models and custom systems into what they do all day: their work. Chefs are ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback